RESEARCH ARTICLE

Open Access

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Vidyalakshmi Chandramohan^{1*} , Xuhui Bao², Xin Yu¹, Scott Parker¹, Charlotte McDowall¹, Yen-Rei Yu³, Patrick Healy⁴, Annick Desjardins¹, Michael D. Gunn³, Matthias Gromeier¹, Smita K. Nair², Ira H. Pastan⁵ and Darell D. Bigner¹

Abstract

Background: D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, immunotoxins induce secondary immune responses through the activation of T cells. However, glioblastoma-induced immune suppression is a major obstacle to an effective and durable immunotoxin-mediated antitumor response. We hypothesized that D2C7-IT-induced immune response could be effectively augmented in combination with αCTLA-4/αPD-1/αPD-L1 therapies in murine models of glioma.

Methods: To study this, we overexpressed the D2C7-IT antigen, murine EGFRvIII (dmEGFRvIII), in established glioma lines, CT-2A and SMA560. The reactivity and therapeutic efficacy of D2C7-IT against CT-2A-dmEGFRvIII and SMA560-dmEGFRvIII cells was determined by flow cytometry and in vitro cytotoxicity assays, respectively. Antitumor efficacy of D2C7-IT was examined in immunocompetent, intracranial murine glioma models and the role of T cells was assessed by CD4+ and CD8+ T cell depletion. In vivo efficacy of D2C7-IT/αCTLA-4/αPD-1 monotherapy or D2C7-IT+αCTLA-4/αPD-1 combination therapy was evaluated in subcutaneous unilateral and bilateral CT-2A-dmEGFRvIII glioma-bearing immunocompetent mice. Further, antitumor efficacy of D2C7-IT+αCTLA-4/αPD-1/αPD-L1/αTim-3/αLag-3/αCD73 combination therapy was evaluated in intracranial CT-2A-dmEGFRvIII and SMA560-dmEGFRvIII glioma-bearing mice. Pairwise differences in survival curves were assessed using the generalized Wilcoxon test.

(Continued on next page)

* Correspondence: vidyalakshmi.chandramohan@duke.edu

¹Department of Neurosurgery and the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Medical Sciences Research Building, Rm 181c, Box 3156, Durham, NC 27710, USA

Full list of author information is available at the end of the article

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

(Continued from previous page)

Results: D2C7-IT effectively killed CT-2A-dmEGFRvIII ($IC_{50} = 0.47$ ng/mL) and SMA560-dmEGFRvIII ($IC_{50} = 1.05$ ng/mL) cells in vitro. Treatment of intracranial CT-2A-dmEGFRvIII and SMA560-dmEGFRvIII tumors with D2C7-IT prolonged survival ($P = 0.0188$ and $P = 0.0057$, respectively), which was significantly reduced by the depletion of CD4+ and CD8+ T cells. To augment antitumor immune responses, we combined D2C7-IT with α CTLA-4/ α PD-1 in an in vivo subcutaneous CT-2A-dmEGFRvIII model. Tumor-bearing mice exhibited complete tumor regressions (4/10 in D2C7-IT+ α CTLA-4 and 5/10 in D2C7-IT+ α PD-1 treatment groups), and combination therapy-induced systemic antitumor response was effective against both dmEGFRvIII-positive and dmEGFRvIII-negative CT-2A tumors. In a subcutaneous bilateral CT-2A-dmEGFRvIII model, D2C7-IT+ α CTLA-4/ α PD-1 combination therapies showed dramatic regression of the treated tumors and measurable regression of untreated tumors. Notably, in CT-2A-dmEGFRvIII and SMA560-dmEGFRvIII intracranial glioma models, D2C7-IT+ α PD-1/ α PD-L1 combinations improved survival, and in selected cases generated cures and protection against tumor re-challenge.

Conclusions: These data support the development of D2C7-IT and immune checkpoint blockade combinations for patients with malignant glioma.

Keywords: Immunotoxin, Immune checkpoint inhibitors, EGFR, T cells, Malignant gliomas

Background

The World Health Organization (WHO) has classified gliomas into the following subtypes by histopathological features and genetic characteristics: low-grade astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, anaplastic astrocytoma, and glioblastoma [1]. Glioblastoma is the most frequent and most malignant primary brain tumor in adults. It is composed of highly malignant cells that exhibit widespread infiltration into both adjacent and distant normal brain region, making the tumor highly therapy-resistant [1]. The median survival (MS) of glioblastoma patients treated with the current standard of care, including maximum safe surgical resection, radiotherapy, and concomitant chemotherapy with temozolomide, is 15–18 months [2–5]. Although currently approved therapies have led to a small improvement in glioblastoma patient survival, this improvement is plagued by systemic tissue toxicities and a poor health-related quality of life. Hence, there is a dire need for the development of new therapeutics that are capable of inducing tumor-specific durable responses with reduced morbidity, while preserving neurologic functions in glioblastoma patients.

D2C7 is a novel monoclonal antibody (mAb) that reacts with both the wild-type epidermal growth factor receptor (EGFRwt) and the mutant EGFR variant III (EGFRvIII) (both of which are major glioblastoma driver oncogenes) overexpressed on the surface of cancer cells [6, 7]. We have previously demonstrated the homogeneous reactivity of D2C7 mAb in adult glioblastoma patient samples ($n = 101$) by immunohistochemistry staining [7]. Our analysis demonstrated the positive reactivity of D2C7 mAb in virtually all cells in 100% (50/50) of the samples with *EGFRwt* amplification and in 76% (39/51) of the cases without *EGFRwt* amplification [7]. We have developed a novel cytotoxic therapeutic from D2C7 mAb for the treatment of glioblastoma; a

recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL (D2C7-IT) [8]. D2C7-(scdsFv)-PE38KDEL is a genetically engineered single-chain variable-region antibody fragment (scdsFv), fused to the bacterial toxin, *Pseudomonas* exotoxin A (PE38KDEL). Upon binding to its antigen, D2C7-IT is internalized by receptor-mediated endocytosis. Once internalized, the catalytically active domain of *Pseudomonas* exotoxin A promotes the adenosine diphosphate-ribosylation and inactivation of elongation factor 2, which leads to inhibition of protein synthesis followed by cell death [9]. In preclinical studies, the dual-specific immunotoxin D2C7-IT demonstrated a strong antitumor response against intracranial glioblastoma xenografts expressing EGFRwt only and both EGFRwt and EGFRvIII, resulting in a highly significant increase in survival in the tumor-bearing animals with no viable tumor cells at the termination of the experiment. D2C7-IT is currently being evaluated in a dose-escalation phase I clinical trial for recurrent WHO grade III and IV malignant glioma patients (NCT02303678).

In addition to specifically targeting and killing tumor cells, therapies that are capable of stimulating immune responses are critical for providing long-term protection from tumor recurrence. The involvement of T cells in immunotoxin induced secondary immune responses in subcutaneous tumor models have been previously demonstrated [10, 11]. However, generation of durable antitumor immune responses by tumor-targeted cytotoxic therapies, such as D2C7-IT, is hindered by systemic and local immunosuppression in glioblastoma through the secretion of soluble factors, expression of inhibitory receptors, activation of immunosuppressive regulatory T cells (Tregs), and dysfunction/exhaustion of tumor-reactive T cells [12–19]. In addition, the immune system is also equipped with inhibitory receptors or immune checkpoints that are required for maintenance of self-tolerance and modulation of the

strength of the immune response under physiological conditions. Tumors use immune checkpoint pathways to inhibit tumor-reactive T cells as a mechanism of immune resistance. Accordingly, immune resistance can be overcome by the use of antagonistic antibodies that block inhibitory receptor-ligand interactions and enhance antitumor immunity to generate durable clinical responses. The first immune checkpoint receptor to be clinically targeted was cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is expressed on T cells and regulates the early stages of T cell activation [20]. Blocking CTLA-4 enhances tumor immunity in mouse models of brain tumor [21, 22]. A second immune checkpoint receptor on T cells is programmed cell death protein 1 (PD-1) which controls T cell function in peripheral tissues during inflammation and autoimmunity [20]. PD-1 limits the activity of T cells in the tumor via its ligand, programmed death-ligand 1 (PD-L1), expressed on tumor cells, making PD-1–PD-L1 interaction the major immune suppressive mechanism in tumor tissue. PD-L1 expression in gliomas is related to the tumor grade and is strongly associated with poor outcome [23–25]. In an open-label, phase III study (CheckMate 143), nivolumab (α PD-1) monotherapy compared with bevacizumab failed to improve median overall survival (OS) and objective response rate (ORR) in patients with recurrent glioblastoma; median OS and ORR was 9.8 months and 8% with nivolumab and 10 months and 23% with bevacizumab [26]. However, α PD-1 and radiotherapy/local chemotherapy combinations improved survival in mice with orthotopic gliomas [27, 28]. In addition to CTLA-4 and PD-1, exhausted T-cells exhibit increased expression of additional co-inhibitory receptors including TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), LAG-3 (lymphocyte-activation gene 3), and TIGIT (T cell immunoreceptor with Ig and ITIM domains), broadening the therapeutic repertoire for T cell targeting [16, 29]. Another target for immune checkpoint blockade is CD73, an extracellular nucleotidase found on a variety of human tissue types, including lymphocytes and neurogliaocytes [30]. One of its functions is to convert extracellular adenosine monophosphate into adenosine which causes, among other effects, the dysregulation of immune cell infiltration [31]. CD73 is also highly expressed on glioblastoma cells, positively correlated with EGFR expression, and its upregulation has been shown to both raise adenosine concentrations and lower the number of T cells in the glioblastoma microenvironment [30, 32]. We hypothesize that controlling and eliminating brain tumors requires targeted and effective tumor cell killing by cytotoxic agents and concurrent induction and maintenance of antitumor T cell function by blocking inhibitory receptors on T cells.

In the current work, we investigated D2C7-IT-mediated antitumor immunity in immunocompetent animal models

of brain tumors. Our *in vivo* results indicate that CD4 and CD8 T cells are critical for D2C7-IT-induced antitumor response. We further demonstrate that the combination of D2C7-IT and immune checkpoint pathway inhibition elicit an effective and durable antitumor immune response that controls primary tumor growth and prevents tumor recurrence. Our findings support D2C7-IT and T cell inhibitory receptor antagonistic antibody combination therapy might improve the outcome of glioblastoma patients.

Methods

In vivo subcutaneous tumor model

C57BL/6 J mice (≈ 20 g, 6–8 weeks, female, The Jackson Laboratory) were anesthetized by isoflurane inhalation, and the appropriate flanks were shaved. A total of 3×10^6 CT-2A-dmEGFRvIII-Luc tumor cells were prepared in 100 μ L of Phosphate-buffered saline (PBS) and injected into the right flank. When the right tumor volumes reached an average of 100 mm³, mice ($n = 10$) were randomized into different treatment groups based on tumor volume. A total of four doses (1.5 μ g/dose, prepared in 100 μ L of 0.1% PBS-mouse serum albumin [MSA]) of D2C7-IT or control P588-IT were delivered by intratumoral injections every four days. Four doses of 250 μ g/dose α PD-1 antibody (Clone RMP1–14, Bio-X-Cell) or 100 μ g/dose α CTLA-4 antibody (Clone UC10-4F10–11, Bio-X-Cell) were delivered by intraperitoneal injections on the same days as D2C7-IT.

Mice from the efficacy studies surviving symptom-free for > 70 days post initial tumor implantation were re-challenged on day 72. Briefly, 1×10^6 antigen negative CT-2A cells were implanted on the left flank of the surviving mice. A total of five C57BL/6 J mice (6–8 weeks, female) were used as controls.

Mice from the re-challenge studies surviving symptom-free for > 120 days post initial tumor implantation were re-challenged on day 126. Briefly, 3×10^5 CT-2A-dmEGFRvIII-Luc cells were implanted intracranially on the contralateral hemisphere of the surviving mice using the coordinates described below. A total of five C57BL/6 J mice (6–8 weeks, female) were used as controls.

For the bilateral tumor model, on day 0, a total of 3×10^6 and 1×10^6 CT-2A-dmEGFRvIII-Luc cells were injected into the right and left flank of C57BL/6 mice, respectively. When the right tumor volumes reached an average of 100 mm³, mice ($n = 10$) were randomized into different treatment groups and were treated every three days as described above except a higher dose of D2C7-IT (4.5 μ g/dose) was used in this study to induce stronger tumor cell killing.

Tumors were measured twice weekly with a handheld Vernier caliper, and the tumor volumes were calculated in cubic millimeters by using the formula: $([\text{length}] \times [\text{width}^2])/2$. Animals were tested out of the study when tumor volume was 1500–2000 mm³ (Additional file 2).

Results

Generation of immunocompetent brain tumor models for D2C7-IT therapy

Since D2C7-IT binds human EGFR but not mouse EGFR (mEGFRwt/mEGFRvIII), we engineered D2C7-IT for studies in syngeneic, immunocompetent murine models. The D2C7 epitope is composed of a conformational determinant of 55 amino acids. There is a mismatch of seven amino acids between the human (h) and mouse (m) EGFR sequence in the D2C7 epitope region (Additional file 1: Figure S1). To facilitate D2C7 binding to mEGFRvIII, the DNA sequence corresponding to the seven amino acids in the mEGFRvIII protein sequence was mutated by site-directed mutagenesis to create the human D2C7 epitope. This chimeric construct was designated D2C7 (d)-mouse (m)-EGFRvIII (dmEGFRvIII) and was used to generate brain tumor cell lines for D2C7-IT targeted therapy.

Binding of the D2C7 mAb and cytotoxicity of D2C7-IT against mouse brain tumor cell lines

The astrocytic brain tumor cell lines CT-2A and SMA560 were transduced with dmEGFRvIII and luciferase (Luc) constructs to establish the CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc cell lines. The D2C7 mAb exhibited binding to the brain tumor cell lines CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc (Fig. 1a and c). The cytotoxicity (IC_{50} measurements) of D2C7-IT on the CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc cells were 0.47 ng/mL and 1.05 ng/mL, respectively (Fig. 1b and d). The control immunotoxin, P588-IT, exhibited no (>1000 ng/mL) or non-specific (510 ng/mL) cytotoxic activity against both CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc cells, respectively.

Determination of D2C7-IT maximum tolerated dose (MTD)

To determine the MTD of D2C7-IT for intracranial treatment, CT-2A-dmEGFRvIII-Luc tumor-bearing C57BL/6 immunocompetent mice were treated with 0.03, 0.1, 0.3, and 1 μ g of D2C7-IT by CED for 72 h. Significant acute toxicity (4/8 mice total; Additional file 1: Figure S2) was observed with the highest dose of D2C7-IT (1 μ g) after the 72-h infusion. Total doses of 0.1 μ g and 0.3 μ g of D2C7-IT that had no toxicity-associated mortality were chosen as the appropriate dose for further evaluation.

Antitumor efficacy of D2C7-IT therapy in intracranial glioma models

Orthotopic models of brain tumors were established with CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc cell lines in C57BL/6 and VM/Dk immunocompetent mice, respectively. Based on MS in untreated mice, days 4 and 6 post-tumor implantations were selected as the optimal time

to initiate D2C7-IT infusion by CED in SMA560-dmEGFRvIII-Luc (MS = 13) and CT-2A-dmEGFRvIII-Luc (MS = 15) tumors, respectively. Mice were examined by bioluminescence imaging (BLI) on days 3 (SMA560-dmEGFRvIII-Luc) and 5 (CT-2A-dmEGFRvIII-Luc) and were randomized into different treatment groups based on total flux. In the CT-2A-dmEGFRvIII-Luc intracranial tumor model, orthotopic delivery of 0.1 μ g ($P = 0.0378$) or 0.3 μ g ($P = 0.0188$) of D2C7-IT corresponded with an increase in MS of 33 and 37% compared to vehicle control, respectively (Fig. 2a). Similarly, in the SMA560-dmEGFRvIII-Luc intracranial tumor model, increases in MS of 35 and 39% were observed post 0.1 μ g ($P = 0.0073$) or 0.3 μ g ($P = 0.0057$) of D2C7-IT infusion compared to control, respectively (Fig. 2b). Thus, D2C7-IT generated significant improvement in survival in two different immunocompetent mouse models of brain tumors. Next, we compared the efficacy of D2C7-IT and control immunotoxin P588-IT on tumor antigen positive CT-2A-dmEGFRvIII-Luc and tumor antigen negative parental CT-2A cell lines, respectively (Additional file 1: Figure S3). In the CT-2A-dmEGFRvIII-Luc intracranial tumor model, orthotopic delivery of 0.1 μ g of D2C7-IT generated a 164% increase in MS compared to vehicle control ($P < 0.0001$) (Additional file 1: Figure S3A), and at the end of the study period there were three tumor-free mice in the D2C7-IT monotherapy group. Neither tumor-free mice nor an increase in the MS was observed in control P588-IT group compared to vehicle control (Additional file 1: Figure S3A), thus eliminating the possibility of a nonspecific effect of the PE38K-DEL on the tumor microenvironment. Orthotopic delivery of 0.1 μ g of D2C7-IT or P588-IT failed to increase MS in the parental CT-2A intracranial tumor model, thereby demonstrating the specificity of D2C7-IT to EGFRvIII tumor antigen (Additional file 1: Figure S3B).

Effect of CD4+ and CD8+ T cell depletion on D2C7-IT-mediated antitumor response

To determine if D2C7-IT activates secondary immune responses, we depleted T lymphocyte subsets in intracranial CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc glioma-bearing mice ($n = 10$ /group). D2C7-IT (0.3 μ g) delivered by CED for 72 h extended MS from 21 to 25 and 13 to 19 days against CT-2A-dmEGFRvIII-Luc (Fig. 3a) and SMA560-dmEGFRvIII-Luc tumors (Fig. 3b), respectively. The therapeutic efficacy of D2C7-IT was completely abolished upon CD4+ or CD8+ T cell depletion in the CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc models (Fig. 3). Thus, in addition to the direct cytotoxic effect on tumor cells, D2C7-IT generates a secondary CD4+ and CD8+ T cell immune response.

PD-1 and FoxP3 expression in T cells in mouse models of brain tumors

Since T cells contributed to D2C7-IT-mediated antitumor response (Fig. 3) and glioblastomas support an immunosuppressive microenvironment [13, 14, 18, 19], we examined the phenotype of CD4⁺ and CD8⁺ T cells and tumor cells in CT-2A-dmEGFRvIII-Luc (day 6 and end-stage), and SMA560-dmEGFRvIII-Luc (day 4 and end-stage) intracranial tumors. Flow cytometry analysis demonstrated the expression of inhibitory receptor PD-1 on CD4⁺ and CD8⁺ T cells and its ligand PD-L1 on tumor cells in CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc tumors (Additional file 1: Figure S4). Similarly, immunosuppressive FoxP3⁺ CD4⁺ T cells were present in both CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc intracranial tumors (Additional file 1: Figure S4B and S4F). Multiplex immunofluorescence analysis showed the expression of PD-1 on CD8⁺ and FoxP3 on CD4⁺ T cells in CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc tumors (Additional file 1: Figure S5A-B, left panels). PD-L1 expression on tumor cells in CT-2A-dmEGFRvIII-Luc and

SMA560-dmEGFRvIII-Luc tumors (Additional file 1: Figure S5A-B, right panels) was confirmed by immunohistochemistry. Our data indicate that combining D2C7-IT with antibodies that block the immune checkpoints PD-1 (to reactivate exhausted tumor-specific T cells) and CTLA-4 (to inhibit immunosuppressive Tregs), or PD-L1 (to block PD1/PDL1 pathway) may reinstate immunosurveillance in brain tumors.

D2C7-IT and αPD-1/αCTLA-4 combination therapy in the subcutaneous CT-2A-dmEGFRvIII-Luc model

The in vivo efficacy of D2C7-IT/αCTLA-4/αPD-1 monotherapy or D2C7-IT+αCTLA-4/αPD-1 combination therapy was evaluated in subcutaneous CT-2A-dmEGFRvIII-Luc bearing C57BL/6 immunocompetent mice. In the in vivo subcutaneous CT-2A-dmEGFRvIII-Luc model, four cycles of the D2C7-IT (but not αCTLA-4/αPD-1) monotherapies and D2C7-IT+αCTLA-4/αPD-1 combination therapies generated a significant delay in tumor growth compared to the control immunotoxin (P588-IT) treatment groups (Fig. 4a). Importantly, complete tumor regressions were only

A C57BL/6: CT-2A-dmEGFRvIII-Luc **B VM/Dk: SMA560-dmEGFRvIII**

Fig. 2 Dose-response comparison of two different D2C7-IT concentrations in orthotopic glioma models. Treatment schedule, survival curves, and median survival are shown for C57BL/6 J mice bearing intracranial CT-2A-dmEGFRvIII-Luc tumors (a) and VM/Dk mice bearing intracranial SMA560-dmEGFRvIII-Luc tumors (b) infused with either vehicle control, 0.1µg D2C7-IT, or 0.3µg D2C7-IT. The *p*-values generated from the generalized Wilcoxon test are provided for both tumor models

observed in the D2C7-IT+αCTLA-4 ($n = 4/10$) and D2C7-IT+αPD-1 ($n = 5/10$) combination therapy groups (Fig. 4b). Further, surviving mice from the D2C7-IT+αCTLA-4 ($n = 4/10$) and D2C7-IT+αPD-1 ($n = 5/10$) combination therapy groups failed to develop tumors upon subcutaneous re-challenge (day=72) with the parental CT-2A cell line that does not express the target antigen, EGFR, indicating that the combination therapy induced broadly protective antitumor immunity (Fig. 4c). We also observed the induction of protective antitumor immunity in mice re-challenged intracranially (day=126) with the target antigen-expressing CT-2A-dmEGFRvIII-Luc cells (Fig. 4d).

We next investigated the efficacy of D2C7-IT/αCTLA-4/αPD-1 monotherapies or D2C7-IT+αCTLA-4/αPD-1 combination therapies in vivo in a bilateral subcutaneous CT-2A-dmEGFRvIII-Luc model. On day 0, a total of 3×10^6 and 1×10^6 CT-2A-dmEGFRvIII-Luc tumor cells were injected into the right and left flank of C57BL/6 mice, respectively. When the right tumors reached an average volume of 100 mm³, they were treated with four cycles of D2C7-IT/αCTLA-4/αPD-1 monotherapies or D2C7-IT+αCTLA-4/αPD-1 combination therapies, while the left tumors were left untreated. The D2C7-IT monotherapy and D2C7-IT+αCTLA-4/αPD-1 combination therapies led to significant growth delay of the

right tumors (Fig. 5a). On day 35 post-tumor implantation, a significant tumor growth delay was observed in the left untreated tumors as compared to the vehicle control group in mice treated with D2C7-IT/αCTLA-4/αPD-1 monotherapies (exact Wilcoxon rank-sum $P < 0.05$) or D2C7-IT+αCTLA-4/αPD-1 combination therapies (exact Wilcoxon rank-sum $P < 0.01$) (Fig. 5b). Compared to D2C7-IT monotherapy (day 43 post-tumor implantation), a significant decrease in left tumor volume was observed with the D2C7-IT+αCTLA-4/αPD-1 combination therapies (exact Wilcoxon rank-sum $P < 0.05$) (Fig. 5c), indicating the induction of a systemic immune response.

D2C7-IT and αPD-1/αCTLA-4 combination therapies in the intracranial CT-2A-dmEGFRvIII-Luc glioma model

Since our subcutaneous studies indicated improved survival with or D2C7-IT+αCTLA-4/αPD-1 combination therapies (Figs. 4 and 5), we next evaluated their efficacy in intracranial CT-2A-dmEGFRvIII-Luc glioma-bearing C57BL/6 mice. In comparison to the vehicle control treatment group, we observed a ≈ 30 –60% increase in MS with the D2C7-IT/αPD-1 monotherapies, an 80% increase in MS with the D2C7-IT+αCTLA-4 combination therapy, and a 120% increase in MS with the D2C7-IT

+ α PD-1 combination therapy (Fig. 6a). At the end of the study period, there was one mouse each that was tumor free in the α CTLA-4/ α PD-1 monotherapy groups (Fig. 6a), and there were 4 mice and 1 mouse that were tumor free in the D2C7-IT+ α PD-1 (Fig. 6a) and D2C7-IT+ α CTLA-4 (Fig. 6a), combination therapy groups, respectively. Surviving mice from both the monotherapy and combination therapy groups were re-challenged intracranially on day 60 with CT-2A-dmEGFRvIII-Luc cell line (Fig. 6b). While all the control mice developed tumors, all of the surviving mice from either the monotherapy or the combination therapy groups resisted tumor re-challenge (Fig. 6b), indicative of the generation of a systemic antitumor immune response.

Antitumor efficacy of D2C7-IT and α PD-1/ α PD-L1/ α Tim-3/ α Lag-3/ α CD73 combination therapies against intracranial gliomas

Since our initial intracranial study (Fig. 6a) demonstrated a significant increase in survival when D2C7-IT was used in combination with α PD-1 and α CTLA-4 antibodies, and glioblastomas are known to express additional checkpoint inhibitors including PD-L1/Tim-3/Lag-3/CD73 [16, 23, 32] we extended our analysis to

include blockade of these immune checkpoint inhibitors as possible therapeutic agents. In comparison to the vehicle control group, we observed a $\approx$ 52–100% increase in MS with the D2C7-IT monotherapy and D2C7-IT+ α PD-1/ α Tim-3/ α Lag-3/ α CD73 combination therapies, and a $>$ 286% increase in MS with the D2C7-IT+ α PD-L1 combination therapy (Fig. 7a). At the end of the study there were tumor-free mice in the D2C7-IT monotherapy and different combination therapy groups, with the maximum numbers observed in the D2C7-IT+ α PD-L1 combination therapy group (Fig. 7a). On day 77 post-tumor implantation all surviving mice were intracranially re-challenged with target antigen-negative 2×10^5 CT-2A parental line, along with five naïve controls (Fig. 7b). All of the naïve control mice developed tumors and failed to survive the re-challenge, while none of the mice from the D2C7-IT monotherapy or D2C7-IT+immune checkpoint inhibitor combination developed tumors (Fig. 7b).

The D2C7-IT+ α PD-1/ α PD-L1/ α Tim-3/ α Lag-3/ α CD73 antibody combination therapy study in the SMA560-dmEGFRvIII-Luc glioma model generated a $\approx$ 24–100% increase in the MS of the D2C7-IT monotherapy and the different combination therapy groups (Fig. 7c). Three

mice remained alive in each of the D2C7-IT+αPD-1 and D2C7-IT+αPD-L1 combination therapy groups at the end of the study (Fig. 7c). These mice, in addition to five naïve controls, were intracranially re-challenged on day 77 with 3×10^4 SMA560 parental line (Fig. 7d). All five naïve control mice succumbed to tumors, while all the mice from the D2C7-IT+αPD-1 and D2C7-IT+αPD-L1 combination therapy groups remained tumor free (Fig. 7d).

Additional experiments were performed to compare the efficacy of the D2C7-IT/αPD-L1/αTim-3/αLag-3/αCD73 monotherapies and D2C7-IT+αPD-L1/αTim-3/αLag-3/αCD73 combination therapies (Additional file 1: Figure S6). We observed a 142% increase in MS with the D2C7-IT monotherapy and a 232% increase with both αPD-L1 monotherapy and D2C7-IT+αPD-L1 combination therapy (Additional file 1: Figure S6A). At the end of the study, there were 4–5 alive mice in the D2C7-IT or αPD-L1 monotherapy groups and 8/8 alive mice in the D2C7-IT+αPD-L1 combination therapy group (Additional file 1: Figure S6A). In comparison to the D2C7-IT monotherapy, we did not observe significant improvement in survival with αTim-3/αLag-3/αCD73 monotherapies and D2C7-IT+αTim-3/αLag-3/αCD73 combination therapies (Additional file 1: Figure S6B-D).

Discussion

Glioblastomas are highly heterogeneous, inherently aggressive, and immunosuppressive tumors that evade the host immune system resulting in suboptimal responses to immunotherapy. D2C7-IT is a cytotoxic agent that targets both EGFRwt and mutant EGFRvIII. In this study, we investigated the mechanism of D2C7-IT-induced antitumor response. Our results indicate that in addition to eliminating tumor cells in a targeted manner, D2C7-IT induce T cell responses as evidenced by the fact that depletion of T cells reduces IT-mediated antitumor response. Immune checkpoint therapies that block inhibitory receptors on T cells are used to overcome tumor immune suppression and improve treatment outcome for patients with melanoma and lung cancer, but not glioblastoma [26, 33–35]. Interestingly, checkpoint inhibitors only benefit a small subset of patients, specifically those who have a pre-existing antitumor immune response [36]. We, therefore, investigated if the antitumor efficacy of D2C7-IT can be augmented with immune checkpoint blockade in murine glioma models. Our findings indicate that D2C7-IT in combination with PD-1/PD-L1 blockade elicit targeted tumor cell cytotoxicity and an effective and durable adaptive T cell response.

We used two immunocompetent murine malignant glioma models CT-2A-dmEGFRvIII-Luc and SMA560-

dmEGFRvIII-Luc, for the assessment of D2C7-IT and immune checkpoint inhibitor combination efficacy. In intracranial CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc tumor models, orthotopic delivery of D2C7-IT generated significant improvement in survival ($P < 0.05$) (Fig. 2). Further, depletion studies demonstrated complete abrogation of D2C7-IT specific antitumor responses in the absence of CD4⁺ or CD8⁺ T cells (Fig. 3). Our data suggest that the remarkable response observed in phase I studies with the ITs, TP-38 (patient surviving > 5 years post-therapy) [37] and IL13-PE38QQR (prolonged progression-free survival beyond one and two years in 15/46 glioblastoma patients) [38] could be attributed to IT-mediated induction of T cell immune response. In the ongoing phase I clinical trial (NCT02303678), 36 patients have been treated with D2C7-IT. Encouraging efficacy results are observed, with fourteen patients remaining alive and one patient continuing to persist disease-free > 29.4 months after D2C7-IT infusion [39], suggesting the involvement of T cell response.

Since inhibitory receptors are known to dampen immune response in malignant brain tumors [16], we examined the presence of such receptors on T cells in intracranial tumors. Examination of CT-2A-dmEGFRvIII-Luc and SMA560-dmEGFRvIII-Luc tumors established the expression of

inhibitory receptors PD-1 and FoxP3 on T cells and inhibitory ligand PD-L1 on tumor cells. This data led us to examine the efficacy of D2C7-IT and immune checkpoint inhibitor combinations in the murine glioma models. Due to the complexity of intracranial tumor models involving multiple treatment groups (≥ 6) and size ($n = 10/\text{group}$) we were interested in conducting the initial antitumor efficacy studies in subcutaneous glioma models and therefore examined the immune cell composition in subcutaneous and intracranial tumors by flow cytometry. Except for microglia, flow cytometry analysis revealed similar immune cell composition in subcutaneous and intracranial glioma models. Therefore we chose to pursue the preliminary antitumor efficacy assessment of D2C7-IT and immune checkpoint inhibitor combinations in subcutaneous murine glioma models and subsequently validated the results in intracranial tumor models. In the subcutaneous CT-2A-dmEGFRvIII-Luc model significant tumor growth delays and cures were observed specifically in the combination therapy groups (Fig. 4). Additionally, subcutaneous and intracranial re-challenge of surviving tumor-free mice demonstrated the induction of a systemic immune response against CT-2A/CT-2A-dmEGFRvIII-Luc tumors post D2C7-IT+αCTLA-4/αPD-1

combination therapies (Fig. 4). Finally, intratumoral injections of D2C7-IT combined with systemic delivery of α CTLA-4/ α PD-1 induced a secondary immune response and promoted regression of a distant tumor (Fig. 5). These findings indicate that the combination therapy potentiates immune activation at the local tumor milieu which then spreads systemically and eliminates tumors at distant sites.

Next, we examined the efficacy of the D2C7-IT + α CTLA-4/ α PD-1 combination therapy in the intracranial CT-2A-dmEGFRvIII-Luc glioma model. Similar to our sub-cutaneous study significant tumor growth delays, cures, and resistance to tumor re-challenge were observed in the combination therapy groups (Fig. 6). Due to the incidence of severe immune-related adverse events in patients receiving α CTLA-4 antibodies in the clinic, we decided not to pursue the D2C7-IT+ α CTLA-4 combination [35, 40]. We also explored the therapeutic benefit of additional checkpoint inhibitors including α PD-1/ α PD-L1/ α Tim-3/ α Lag-3/ α CD73 in combination with D2C7-IT. In both the CT-2A-dmEGFRvIII-Luc and SMA560-dm-EGFRvIII-Luc glioma models, the use of α PD-L1 or α PD-1 antibodies in combination with D2C7-IT proved to be the most effective in increasing MS and mice survival (Fig. 7). The other immune checkpoint inhibitors, α Tim-3/ α Lag-3/ α CD73, tested in

combination with D2C7-IT proved to be less effective, failing to match or exceed D2C7-IT+ α PD-L1/ α PD-1 treatments both in MS increase and in the number of surviving mice. All of the surviving mice resisted tumor re-challenge with antigen-negative parental glioma cell line CT-2A indicating the generation of a broadly protective systemic antitumor immunity.

In the absence of real-time tumor visualization, in vivo efficacy of the D2C7-IT and checkpoint inhibitor combination against intracranial tumors is influenced by multiple factors including tumor cell count, tumor size, tumor location, precise delivery of the immunotoxin, and treatment regimen. Unlike subcutaneous tumor models, with the highly aggressive CT-2A-dmEGFRvIII-Luc and SMA560-dm-EGFRvIII-Luc intracranial glioma models, even a minor variability in one of the above factors would cause a significant difference in the therapeutic efficacy. Thus we would hypothesize that one or a combination of the above technical factors contributed to the variability in survival observed post-D2C7-IT and checkpoint inhibitor mono and combination therapies.

Recently it was demonstrated in both CT-2A and SMA560 intracranial tumors that PD-1 was expressed on the majority of CD8⁺ T-cells, and Tim-3 and Lag-3 were predominantly co-expressed with PD-1 [16].

Additionally, in CT-2A orthotopic tumors, PD-1 was shown to be present on $\approx 50\%$ of CD8⁺ T-cells, while Tim-3 and Lag-3 were expressed on $\approx 2\text{--}4\%$ of CD8⁺ T-cells [16]. We believe that the low expression of Tim-3 and Lag-3 in the malignant glioma models contributed to the sub-optimal efficacy of the D2C7-IT + α Tim-3/ α Lag-3 therapies. In the absence of CD73 expression data in the CT-2A and SMA560 tumor models, we hypothesize that lower levels of expression translated into decreased therapeutic efficacy with D2C7-IT + α CD73 therapy.

For all our subcutaneous therapy studies we were able to inject a high dose of D2C7-IT (6–18 μ g total dose) into tumors to achieve a therapeutic response in the absence of non-specific systemic toxicity. However, in our intracranial tumor models, we observed non-specific toxicity at a total dose of D2C7-IT > 0.3 μ g. We believe that D2C7-IT dose limitation prevented us from achieving significant therapeutic benefits with this drug as a single agent. We also used a nonspecific IT, P588-IT, as a control in subcutaneous and intracranial studies. No significant therapeutic benefit from an intratumoral injection of the control IT was observed confirming that antigen-targeted tumor cell killing by D2C7-IT resulted in the generation of systemic immunity. Finally, both CT-2A-dmEGFRvIII-Luc and SMA560-dm-EGFRvIII-Luc glioma models are extremely aggressive with a MS of ≤ 15 days. Achieving significant improvement in MS and the number of tumor-free mice in such aggressive models with a total dose of 0.1 μ g D2C7-IT + α PD-L1/ α PD-1 therapy reinforces the therapeutic benefit of the combinations and provides a strong rationale for clinical translation.

Flow cytometry analysis was undertaken to unravel the role of T cells in the increased efficacy of D2C7-IT + α PD-1/ α CTLA-4 therapies. Preliminary data indicated an increase in both CD4:Treg and CD8:Treg ratio in the CT-2A-dmEGFRvIII-Luc intracranial tumors specifically in the combination therapy groups (Additional file 1: Figure S7). A previous study involving anti-mesothelin IT (SS1P) and α CTLA-4 combination demonstrated a significant increase in CD8⁺ T cells in the mammary tumors in the combination therapy group [41]. However, we did not see an increase in the total number of CD4⁺ or CD8⁺ T cells after D2C7-IT + α PD-1/ α CTLA-4 combinations. An increase in antigen-specific T cells both in the tumor and draining lymph nodes was demonstrated previously post chemotherapy and α PD-1 combinations in an intracranial tumor model with the GL261-Ova cell line [27]. We are in the process of establishing CT-2A-dmEGFRvIII-Trp2 and CT-2A-dmEGFRvIII-Ova cell lines to investigate the presence of antigen-specific T cells post D2C7-IT and checkpoint inhibitor combination therapies. Additionally, flow cytometry analysis failed to show changes in the numbers of microglia,

macrophages, B cells, NK cells, and neutrophils during D2C7-IT/ α PD-1/ α CTLA-4 mono and combination therapies. Future studies will focus on elucidating the mechanism for the improved efficacy of the D2C7-IT + α PD-L1/ α PD-1 combinations.

Finally, in phase II trials, Rindopepimut (CDX-110), a peptide vaccine targeting EGFRvIII, improved overall survival in newly diagnosed GBM patients expressing EGFRvIII [42]. However, in a randomized, double-blinded, phase III trial, despite the induction of an EGFRvIII-specific antibody response in the majority of patients, rindopepimut cohort failed to outperform the control KLH cohort [43]. Preclinical mechanistic studies showed a role for antibody-dependent cellular cytotoxicity (ADCC) in the antitumor response following EGFRvIII peptide vaccination [44]. Effective tumor cell killing by ADCC is dependent on Fc receptor-mediated activation of NK cells, granulocytes, and macrophages and this pathway could be profoundly compromised in highly immunosuppressed GBM patients, in turn, contributing to the failure of phase III rindopepimut trial. In contrast, cytotoxic agents such as D2C7-IT would potentiate direct tumor cell killing and as shown above, will induce a secondary immune response through the activation of T cells. Additionally, D2C7-IT targets both EGFRwt and mutant EGFRvIII proteins. Since *EGFR* modifications and/or focal amplification has been identified in 57% of GBM patients [6] and 67% of patients with EGFR amplification also express EGFRvIII [45], D2C7-IT will likely demonstrate clinical efficacy and will impact GBM therapy. Further lack of randomization and use of potentially outdated historical controls could have skewed the interpretation of results in early phase rindopepimut trials. Nonetheless, patient dropout could be an issue in randomized open-label or double-blinded studies, and we also believe that treating patients with a sham saline CED infusion would be unethical. Therefore potential over interpretation of D2C7-IT efficacy in phase II clinical trials can be avoided by estimating the overall survival of D2C7-IT patients as compared with a matched historical control group (patients who would have been eligible for the D2C7-IT study if the study had been available at the time of their disease progression).

Conclusions

In summary for many cancer types, combination therapies with checkpoint inhibitors are widely regarded as the future of modern oncology. Following this strategy, we investigated the antitumor efficacy of an EGFRwt and EGFRvIII dual-specific immunotoxin, D2C7-IT, and checkpoint inhibitor combinations in mouse models of malignant glioma. Our data indicate that in addition to direct tumor cell killing, D2C7-IT induces T cell-mediated antitumor immune response which can be

augmented by α PD-L1/ α PD-1 combinations. The D2C7-IT and checkpoint inhibitor combination elicit a sustained antitumor immune response that provides long-term protection against tumor re-challenge. Our data support the development of D2C7-IT+ α PD-L1/ α PD-1 combination therapy in the clinic to improve glioblastoma patient survival. Based on our studies in two syngeneic immunocompetent murine glioma models, we plan to conduct a D2C7-IT and α PD-L1 blockade combination clinical trial in patients with recurrent glioblastoma.

Additional files

Additional file 1: Figure S1. D2C7 epitope comparison between human (h) and mouse (ms) EGFR sequence. The diagram shows sequence alignment between the human and mouse EGFR protein with the mismatched amino acids highlighted. **Figure S2.** Toxicity assessment of D2C7-IT in C57BL/6J mice bearing intracranial CT2A-dmEGFRvIII-Luc tumors. Different doses (0.03–1 μ g) of D2C7-IT were delivered intracranially by CED over a 3-day period to C57BL/6J mice (N = 8–9 mice/group) implanted with CT2A-dmEGFRvIII-Luc tumors. Animals were monitored for toxicity related death. Data are expressed as percentage of mice surviving versus time. **Figure S3.** Specificity assessment of D2C7-IT in C57BL/6J mice bearing intracranial CT2A-dmEGFRvIII-Luc (A) or parental CT2A (B) tumors. A total dose of 0.1 μ g of D2C7-IT or control P588-IT were delivered intracranially by CED over a 3-day period to C57BL/6J mice (N = 10 mice/group) implanted with CT2A-dmEGFRvIII-Luc (A) or parental CT2A tumors (B). Animals were monitored for survival. Treatment schedule, survival curves, median survival. And p-values generated from the generalized Wilcoxon test are provided. **Figure S4.** Flow cytometric analysis of immune checkpoint molecule expression on T cells and tumor cells. Intracranial CT2A-dmEGFRvIII-Luc (A–D) and SMA560-dmEGFRvIII-Luc (E–H) tumors were analyzed for the expression of PD-1 on CD4+ and CD8+ T cells, FoxP3 on CD4+CD25+ T cells and PD-L1 on tumor cells. **Figure S5.** Immunofluorescence and immunohistochemistry analysis of checkpoint molecule expression in orthotopic glioma models. Tissue sections from intracranial CT2A-dmEGFRvIII-Luc (A) and SMA560-dmEGFRvIII-Luc (B) tumors were analyzed for the expression of PD-1 and FoxP3 on CD4+ and CD8+ T cells and PD-L1 on tumor cells. **Figure S6.** Anti-tumor efficacy of D2C7-IT and immune checkpoint inhibitor combinations in orthotopic glioma models. (A–D) Survival curve and median survival estimate data are shown for C57BL/6J mice bearing intracranial CT-2A-dmEGFRvIII-Luc tumors treated with vehicle control, D2C7-IT, α PD-L1 (A), α Tim-3 (B), α LAG-3 (C), and α CD73 (D) mono or combination therapies. The p-values generated from the generalized Wilcoxon test are provided for all studies and are not adjusted for multiple testing. **Figure S7.** Comparison of CD4+ T cells:Treg and CD8+ T cells:Treg ratio in orthotopic CT2A-dmEGFRvIII-Luc tumors after D2C7-IT, α CTLA-4, or α PD-1 mono and combination therapies. Intracranial CT2A-dmEGFRvIII-Luc (N=5/6 mice/group) tumors were investigated for the presence of CD4+CD25+FOXP3+ Tregs by flow cytometric analysis. Panels (A) and (B) represent CD4+ T cells:Treg and CD8+ T cells:Treg ratio after D2C7-IT or α PD-1 mono and combination therapies. Panels (C) and (D) represent CD4+ T cells:Treg and CD8+ T cells:Treg ratio after D2C7-IT or α CTLA-4 mono and combination therapies. (PPTX 6598 kb)

Additional file 2: Materials and Methods. (DOCX 28 kb)

Abbreviations

ADCC: Anticancer-dependent cellular cytotoxicity; BLI: Bioluminescence imaging; CED: Convection-enhanced delivery; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; dmEGFRvIII: D2C7 (d)-mouse (m)-EGFRvIII; EGFRvIII: mutant epidermal growth factor receptor variant III; EGFRwt: wild-type epidermal growth factor receptor; h: human; IC: Intracranial; IT: Immunotoxin; LAG-3: Lymphocyte-activation gene 3; Luc: Luciferase; m: mouse; mAb: monoclonal antibody; MS: Median survival; MSA: Mouse serum albumin; MTD: Maximum tolerated dose; NK Cells: Natural Killer Cells; ORR: Objective response rate; OS: Overall survival; PBS: Phosphate-buffered

saline; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; PE: *Pseudomonas* exotoxin A; TIGIT: T cell immunoreceptor with Ig and ITIM domains; TIM-3: T-cell immunoglobulin and mucin-domain containing-3; Tregs: regulatory T cells; WHO: World Health Organization

Acknowledgments

We thank Steven Clayton for his assistance with cell culture, Elizabeth Thomas, Merrie Burnett, and Diane Satterfield for assistance with FFPE sections.

Funding

This work was supported by grants from the Tisch family through the Jewish Communal Fund (D.D. Bigner), Uncle Kory Foundation (V. Chandramohan), the National Institutes of Health (NIH) of the United States: P01 – 5P01CA154291 (D.D. Bigner) and the Outstanding Investigator Award – 1R35CA197264 (D.D. Bigner), and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (J.H. Pastan).

Availability of data and materials

Not applicable

Authors' contributions

VC, XB, XY, SP, CM, YRY, MDG, MG, SKN, and DDB designed, carried out, and/or analyzed in vitro and in vivo animal experiments. PH provided biostatistics consultation. VC, AD, MG, SKN, IHP, and DDB provided feedback and supervised all research. VC, SP, SKN, and DDB wrote the manuscript. All authors read, revised, and approved the final manuscript.

Ethics approval and consent to participate

All experiments were done in accordance with the Institutional Animal Care and Use Committee of Duke University Medical Center (A049–17-02). Animals were maintained in a barrier facility, under pathogen-free conditions according to NIH guidelines.

Consent for publication

Not applicable

Competing interests

D2C7-IT has been licensed to a company, Istari Oncology, Inc. D.D. Bigner and M. Gromeier are co-founders and equity holders in the company. A. Desjardins is an equity holder in the company.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Neurosurgery and the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Medical Sciences Research Building, Rm 181c, Box 3156, Durham, NC 27710, USA. ²Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. ³Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. ⁴Duke Cancer Institute Biostatistics, Duke University Medical Center, Durham, NC 27710, USA. ⁵Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Received: 29 August 2018 Accepted: 8 May 2019

Published online: 29 May 2019

References

1. Louis DN, H. Wiestler OD, Cavenee WK. World health organization histological classification of Tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2016.
2. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):709–22.
3. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):699–708.

4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med*. 2005;352(10):987–96.
5. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. *JAMA*. 2015;314(23):2535–43.
6. Brennan CW, Verhaak RG, McKenna A, Campos B, Nounshmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. *Cell*. 2013;155(2):462–77.
7. Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. *Nucl Med Biol*. 2012;39(1):23–34.
8. Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. *Clin Cancer Res*. 2013;19(17):4717–27.
9. Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. *Clin Dev Immunol*. 2012;2012:480429.
10. Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors. *Clin Cancer Res*. 2006;12(15):4678–86.
11. Ochiai H, Archer GE, Herndon JE 2nd, Kuan CT, Mitchell DA, Bigner DD, et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. *Cancer Immunol Immunother*. 2008;57(1):115–21.
12. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. *Clin Cancer Res*. 2008;14(24):8228–35.
13. Bloch O, Crane CA, Kaur R, Safaei M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. *Clin Cancer Res*. 2013;19(12):3165–75.
14. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. *Cancer Res*. 2006;66(6):3294–302.
15. Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Petersen-Baltussen HM, ter Laan M, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. *J Neuropathol Exp Neurol*. 2015;74(5):390–400.
16. Woroniecka K, Chongsathidkiet P, Rhodin KE, Kemeny HR, Dechant CA, Farber SH, et al. T cell exhaustion signatures vary with tumor type and are severe in glioblastoma. *Clin Cancer Res*. 2018;24(17):4175–86.
17. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. *EMBO J*. 1987;6(6):1633–6.
18. Brooks WH, Caldwell HD, Mortara RH. Immune responses in patients with gliomas. *Surg Neurol*. 1974;2(6):419–23.
19. Mahaley MS Jr, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. *J Neurosurg*. 1977;46(4):467–76.
20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–64.
21. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. *PLoS One*. 2014;9(7):e101764.
22. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. *Clin Cancer Res*. 2007;13(7):2158–67.
23. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. *Neuro-Oncology*. 2016;18(2):195–205.
24. Xue S, Hu M, Iyer V, Yu J. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. *J Hematol Oncol*. 2017;10(1):81.
25. Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. *Oncotarget*. 2016;7(8):8944–55.
26. Reardon DAOA, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia AS, Lim M, Vlahovic G, Sampson J. Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. *Neuro-Oncology*. 2017;19(suppl(3)):iii21.
27. Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. *Sci Transl Med*. 2016;8(370):370ra180.
28. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. *Int J Radiat Oncol Biol Phys*. 2013;86(2):343–9.
29. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. *Immunity*. 2016;44(5):989–1004.
30. Wang B, Wang D, Zhu Z, Wang W, Zhang X, Tang F, et al. The role of extracellular-5'-nucleotidase/CD73 in glioma peritumoral brain edema. *Neurol Sci*. 2016;37(4):603–11.
31. Antonoli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. *Trends Cancer*. 2016;2(2):95–109.
32. Figueiro F, de Oliveira CP, Bergamin LS, Rockenbach L, Mendes FB, Jandrey EH, et al. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment. *Purinergic Signal*. 2016;12(2):303–12.
33. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*. 2015;373(2):123–35.
34. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*. 2015;373(1):23–34.
35. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro-Oncology*. 2018;20(5):674–86.
36. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*. 2014;515(7528):568–71.
37. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. *Neuro-Oncology*. 2008;10(3):320–9.
38. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeyer JM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal study group. *J Clin Oncol*. 2007;25(7):837–44.
39. Desjardins A. Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). 22nd International Conference on Brain Tumor Research and Therapy, Norway, June 24–27, 2018.
40. Bertrand A, Kostine M, Barnette T, Truchetet ME, Schaefferbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med*. 2015;13:211.
41. Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, et al. Combining local immunotoxins targeting Mesothelin with CTLA-4 blockade synergistically eradicates murine Cancer by promoting anticancer immunity. *Cancer Immunol Res*. 2017;5(8):685–94.
42. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. *Neuro-Oncology*. 2015;17(6):854–61.
43. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol*. 2017;18(10):1373–85.
44. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. *Clin Cancer Res*. 2003;9(11):4247–54.
45. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. *Cancer Res*. 2000;60(5):1383–7.